small RNA binding exonuclease protection factor La like 2, pseudogeneGenealiases: []
Q-omics provides the consensus-scored SSBL2P profile across patient tissues and cancer cell-line models. SSBL2P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SSBL2P is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, SSBL2P RNA expression shows 9,772 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, COAD, and UVM as cancer lineages where SSBL2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSBL2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSBL2P survival associations across molecular data types. SSBL2P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSBL2P RNA expression–survival associations across cancer types. High SSBL2P expression shows unfavorable associations in UCEC, KICH, STAD and LUAD, but favorable associations in CESC and THCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify CESC as the clearest survival context for SSBL2P RNA expression.
This table summarizes SSBL2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SSBL2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSBL2P shows lower tumor expression in KICH and PAAD and higher tumor expression in COAD, LIHC, STAD and READ. The COAD box plot shows higher SSBL2P RNA expression in tumor versus normal tissue (log2 FC = +0.227, t-test p < 0.001).
This table shows molecular features associated with SSBL2P in patient tissues and cancer cell lines. In patient samples, SSBL2P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
